<DOC>
	<DOCNO>NCT01571466</DOCNO>
	<brief_summary>30 treated chronic HIV-1 infect patient CD4+ cell count 450 cells/ mm3 randomize 1:2 receive placebo ( n=10 ) vaccine ( n=20 ) week 0 , 4 16 observed Investigation Unit study site one hour follow vaccination . At week 24 stop HAART end study .</brief_summary>
	<brief_title>A Study Evaluate Safety HIV-1 Vaccine MVA-B Chronic HIV-1 Infected Patients Successfully Treated With HAART</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Patient â‰¥ 18 year age ; Voluntarily sign informed consent ; Patient male , female negative pregnancy test prior enrolment ; Patient proven HIV1 infection ( positive antibody HIV1 detectable plasma HIV1 RNA ) ; Patient must stable treatment HAART least 6 month ( HAART define antiretroviral regimen consist least three registered antiretroviral agents* ) ; Mean measure CD4+ cell count 6 month prior start HAART must equal 200 cells/ mm3 Current CD4+ cell count must least 450 cells/ mm3 ; HIVRNA must 50 copies/ mL last 6 month prior inclusion , least two measurement ( occasional call 'blips ' 50 copies/mL permit ) ; Patient one following : sexually active , heterosexually active female , agree use condom partner 14 day prior first vaccination 4 month last , even though use another method contraception , willing undergo pregnancy test screen prior vaccination , male , agree use condom partner day first vaccination 4 month last vaccination . Treatment nonHAART regimen antiretroviral agent prior start HAART ; History CDC class C event ( see Appendix ) ; Interruption HAART course study expect time inclusion ; History exposure &lt; 20 year ago poxvirus base vaccine ; Patient female positive pregnancy test wish pregnancy : Active opportunistic infection , active infection malignancy within 30 day prior screen visit ; Therapy immunomodulatory agent , include cytokine ( e.g . IL2 ) gamma globulin , cytostatic chemotherapy within 90 day prior screen visit ; History allergy vaccine component ; Use anticoagulant medication ; Use investigational drug 90 day prior study entry ; Previous failure antiretroviral and/or mutation confer genotypic resistance antiretroviral therapy Any condition , opinion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>HIV Seronegativity</keyword>
	<keyword>HIV Preventive Vaccine</keyword>
</DOC>